Abstract
Treatment options for hematologic malignancies have been rapidly expanding in the past decade, resulting in better survival outcomes for many patients. Infection is an important cause of morbidity and mortality in this patient population. Cytotoxic chemotherapy has well-studied infectious risks related to the degree and duration of myelosuppression. Targeted therapies and immunotherapies have less clearly predictable infectious risk and diverse effects on immune function. This review discusses contemporary management of hematologic malignancies, followed by special discussion of novel agents, including signaling/small molecule inhibitors, monoclonal antibodies, immunomodulators, and immunotherapies, for treatment of hematologic malignancies with focus on infectious risk.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 289-309 |
| Number of pages | 21 |
| Journal | Infectious disease clinics of North America |
| Volume | 33 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2019 |
Fingerprint
Keywords
- Chemotherapy
- Infection
- Malignant hematology
- Novel agents
- Targeted therapy
PubMed: MeSH publication types
- Journal Article
- Review
Cite this
Chemotherapy and Beyond : Infections in the Era of Old and New Treatments for Hematologic Malignancies. / Atkins, Sarah; He, Fiona.
In: Infectious disease clinics of North America, Vol. 33, No. 2, 2019, p. 289-309.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Chemotherapy and Beyond
T2 - Infections in the Era of Old and New Treatments for Hematologic Malignancies
AU - Atkins, Sarah
AU - He, Fiona
PY - 2019
Y1 - 2019
N2 - Treatment options for hematologic malignancies have been rapidly expanding in the past decade, resulting in better survival outcomes for many patients. Infection is an important cause of morbidity and mortality in this patient population. Cytotoxic chemotherapy has well-studied infectious risks related to the degree and duration of myelosuppression. Targeted therapies and immunotherapies have less clearly predictable infectious risk and diverse effects on immune function. This review discusses contemporary management of hematologic malignancies, followed by special discussion of novel agents, including signaling/small molecule inhibitors, monoclonal antibodies, immunomodulators, and immunotherapies, for treatment of hematologic malignancies with focus on infectious risk.
AB - Treatment options for hematologic malignancies have been rapidly expanding in the past decade, resulting in better survival outcomes for many patients. Infection is an important cause of morbidity and mortality in this patient population. Cytotoxic chemotherapy has well-studied infectious risks related to the degree and duration of myelosuppression. Targeted therapies and immunotherapies have less clearly predictable infectious risk and diverse effects on immune function. This review discusses contemporary management of hematologic malignancies, followed by special discussion of novel agents, including signaling/small molecule inhibitors, monoclonal antibodies, immunomodulators, and immunotherapies, for treatment of hematologic malignancies with focus on infectious risk.
KW - Chemotherapy
KW - Infection
KW - Malignant hematology
KW - Novel agents
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85063517158&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063517158&partnerID=8YFLogxK
U2 - 10.1016/j.idc.2019.01.001
DO - 10.1016/j.idc.2019.01.001
M3 - Review article
C2 - 30935703
AN - SCOPUS:85063517158
VL - 33
SP - 289
EP - 309
JO - Infectious Disease Clinics of North America
JF - Infectious Disease Clinics of North America
SN - 0891-5520
IS - 2
ER -